- Home
- CRNX vs NG Comparison
CRNX vs NG Comparison
Compare CRNX & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | NG |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CRNX | NG |
|---|---|---|
| Price | $38.43 | $7.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $76.75 | $12.22 |
| AVG Volume (30 Days) | 928.8K | ★ 2.8M |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | N/A |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $3.37 |
| 52 Week High | $57.99 | $14.40 |
Technical Indicators
Market Signals| Indicator | CRNX | NG |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 34.94 |
| Support Level | $33.19 | $5.81 |
| Resistance Level | $45.32 | $10.44 |
| Average True Range (ATR) | 1.46 | 0.54 |
| MACD | -0.03 | -0.17 |
| Stochastic Oscillator | 27.17 | 0.43 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.